Clovis Oncology Reports Results of Rubraca (rucaparib) in P-III ARIEL3 Study for Advanced Ovarian Cancer

Clovis Oncology Reports Results of Rubraca (rucaparib) in P-III ARIEL3 Study for Advanced Ovarian Cancer

Shots:

  • The P-III ARIEL3 study results involves assessing of Rubraca (rucaparib, 600mg, bid) vs PBO in 564 patients in a ratio (2:1) with platinum-sensitive recurrent ovarian cancer including patients with an epithelial ovarian, fallopian tube or primary peritoneal cancer
  • The P-III ARIEL3 study results: IIT population & BRCA mutation, Mean QA-PFS in (12.02 vs 5.74 & 15.28 vs 5.92 mos.); Mean Q-TWiST (13.32 vs 6.44 & 16.42 vs 6.70 mos.); Q-TWiST (13.16 vs 6.40 & 16.24 vs 6.68 mos.) respectively
  • Rubraca (rucaparib) is an oral PARP1, PARP2 and PARP3 inhibitor and has received FDA’s approval as a monothx. for the maintenance treatment of recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in Apr’18

Click here to read full press release/ article | Ref: BusinessWire | Image: Linkedin